Given Imaging Ltd (NASDAQ: GIVN), a world leader in GI medical
devices and pioneer of capsule endoscopy, today announced that
investigators will present data from over 80 studies that provide
new information about the benefits of using Given Imaging's
products to detect, monitor and measure a range of gastrointestinal
conditions at the upcoming American College of Gastroenterology
(ACG) 2012 Annual Meeting taking place October 19-24, 2012 in Las
Vegas, and the 20th United European Gastroenterology Week taking
place October 20-24, 2012 in Amsterdam, The Netherlands. Given
Imaging's exhibition booths at both conferences will feature Given
Imaging's entire product portfolio including the recently acquired
SmartPill® GI monitoring system, an ingestible capsule that uses
sensor technology to measure pH, pressure and temperature in the GI
tract. The Company will also unveil its newest version of
esophageal manometry analysis software, ManoView™ ESO v3.0.
"Given Imaging's mission is to provide physicians with
innovative tools that help them better detect, monitor and,
ultimately, treat GI diseases," said Homi Shamir, President and
CEO, Given Imaging. "The studies that will be presented at these
two important medical meetings show that our products continue to
provide new, clinically-relevant information to the GI
community."
Given Imaging at American College of
Gastroenterology 2012 Annual Meeting
Given Imaging will be exhibiting at ACG at booth #1325. Key
presentations on its PillCam capsule endoscopy platform and GI
functional diagnostics products will be presented throughout the
conference. On Tuesday, October 23rd, the Capsule Endoscopy
Hands-on Workshop featuring PillCam capsule endoscopy will take
place from 10:30 am - 1:30 pm PDT. The Esophageal Motility Hands-on
Workshop featuring Bravo pH monitoring, Digitrapper pH-Z monitoring
and ManoScan™ high resolution manometry will also take place from
2:00 - 4:30 pm PDT.
Given Imaging at the 20th United European Gastroenterology
Week
Given Imaging will be exhibiting its products, including PillCam
COLON, throughout UEGW at booth #56. During the conference, key
studies on the PillCam capsule endoscopy platform, Bravo pH
monitoring system and ManoScan high resolution manometry platform
will be presented on Monday, October 22nd from 9 am - 5 pm CEST (3
am - 11 am EDT) including:
- Safety of Small Bowel Capsule Endoscopy for
Patients with Established Crohn's Disease (PO203)
- Diagnostic Yield of Capsule Endoscopy in
Refractory Celiac Disease (PO530)
- Second-Generation Colon Capsule Endoscopy for
Colorectal Cancer Screening in Patients Unable or Unwilling to
Perform Colonoscopy (PO103)
- Reflux Associated Symptoms Per Day and Symptom
Index With Confidence Intervals: New Indices of Reflux-Symptom
Association for Diagnosis of Reflux Disease that Improve Prediction
of Treatment Outcome from Prolonged pH-Monitoring (PO446)
All data presented at UEGW will be embargoed until Monday,
October 22th at 12:01am CEST (Sunday, October 21st at 6:01 pm
EDT).
About ACG The American College of
Gastroenterology is a recognized leader in educating GI
professionals and the general public about digestive disorders.
Their mission is to serve the evolving needs of physicians in the
delivery of high quality scientific, humanistic and cost-effective
health care to gastroenterology patients. For more information,
visit http://gi.org.
About United European Gastroenterology
Federation UEGF, or United European Gastroenterology
Federation, is a professional non-profit organization combining all
the leading European societies concerned with digestive disease.
Together, their member societies represent over 22,000 specialists,
working across medicine, surgery, pediatrics, GI oncology and
endoscopy. This makes UEGF the most comprehensive organization of
its kind in the world, and a unique platform for collaboration and
the exchange of knowledge.
UEGF's mission is continually to improve standards of care in
gastroenterology, and promote ever greater understanding of
digestive and liver disease -- among the public and medical experts
alike. As part of that work, it runs a number of education and
training courses facilitated by highly respected experts. UEFG also
organizes UEG Week -- the largest and most prestigious meeting of
its kind in Europe. UEG Week has been running since 1992, in a
variety of major cities, and now attracts more than 14,000 people
from across the world. For more information, please visit
www.ueg.eu.
About Given Imaging Ltd. Since pioneering
the field of capsule endoscopy in 2001, Given Imaging has become a
world leader in GI medical devices, offering health care providers
a range of innovative options for visualizing, diagnosing and
monitoring the digestive system. The company offers a broad product
portfolio including PillCam® capsule endoscope for the small bowel,
esophagus and colon. The company also offers industry-leading GI
functional diagnostic solutions including ManoScan™ high-resolution
manometry, Bravo® capsule-based pH monitoring, Digitrapper® pH-Z
impedance, and the SmartPill® GI monitoring systems. Given Imaging
is committed to delivering breakthrough innovations to the GI
community and supporting its ongoing clinical needs. Given
Imaging's headquarters are located in Yoqneam, Israel, with
operating subsidiaries in the United States, Germany, France,
Japan, Australia, Vietnam, Hong Kong and Brazil. For more
information, please visit www.givenimaging.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, projections about our business and
our future revenues, expenses and profitability. Forward-looking
statements may be, but are not necessarily, identified by the use
of forward-looking terminology such as "may," "anticipates,"
"estimates," "expects," "intends," "plans," "believes," and words
and terms of similar substance. Forward-looking statements involve
known and unknown risks, uncertainties and other factors which may
cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any
future events, results, performance, circumstances or achievements
expressed or implied by such forward-looking statements. Such
forward-looking statements include statements relating to the
Company exploring strategic alternatives and considering possible
strategic transactions involving the Company. Factors that could
cause actual events, results, performance, circumstances or
achievements to differ from such forward-looking statements
include, but are not limited to, the ability of the Company to
reach agreement on any strategic alternative and/or to complete any
such alternative, as well as the following: (1) our ability to
develop and bring to market new products, (2) our ability to
successfully complete any necessary or required clinical studies
with our products, (3) our ability to receive regulatory clearance
or approval to market our products or changes in regulatory
environment, (4) our success in implementing our sales, marketing
and manufacturing plans, (5) the level of adoption of our products
by medical practitioners, (6) the emergence of other products that
may make our products obsolete, (7) lack of an appropriate bowel
preparation materials to be used with our PillCam COLON capsule,
(8) protection and validity of patents and other intellectual
property rights, (9) the impact of currency exchange rates, (10)
the effect of competition by other companies, (11) the outcome of
significant litigation, (12) our ability to obtain reimbursement
for our product from government and commercial payors, (13)
quarterly variations in operating results, (14) the possibility of
armed conflict or civil or military unrest in Israel, (15) the
impact of global economic conditions, (16) our ability to
successfully integrate acquired businesses, (17) changes and
reforms in applicable healthcare laws and regulations, (18) quality
issues and adverse events related to our products, such as capsule
retention, aspiration and failure to attach or detach, bleeding or
perforation that could require us to recall products and impact our
sales and net income, and (19) other risks and factors disclosed in
our filings with the U.S. Securities and Exchange Commission,
including, but not limited to, risks and factors identified under
such headings as "Risk Factors," "Cautionary Language Regarding
Forward-Looking Statements" and "Operating Results and Financial
Review and Prospects" in the Company's Annual Report on Form 20-F
for the year ended December 31, 2011. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Except to the
extent expressly required under applicable law, the Company
undertakes no obligation to release publicly any revisions to any
forward-looking statements, to report events or to report the
occurrence of unanticipated events.
For further information contact: Fern Lazar/David Carey
Lazar Partners Ltd. 1-212-867-1762 flazar@lazarpartners.com
dcarey@lazarpartners.com Israel Investor Contact: Nava Ladin
Gelbart Kahana Investor Relations +972-3-6074717
nava@gk-biz.com
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024